Novo Nordisk CFO Karsten Munk Knudsen speaks on Bloomberg Television about earnings, tariffs and the impact of compounding in the US, which he cites as a reason for the drugmaker’s lower quarterly results and outlook cut. Speaking on Bloomberg Television, Knudsen says Novo is affected by compounding “significantly more” than its competitor Eli Lilly. (Source: Bloomberg)
www.bloomberg.com
#Novo #Nordisk #CFO #Wegovy #Tariffs #Compounding
Novo Nordisk CFO on Wegovy, Tariffs, US Compounding
